Haber Stacy L, Benson Vera, Buckway Casey J, Gonzales Jennifer M, Romanet David, Scholes Brittany
College of Pharmacy-Glendale, Midwestern University, Glendale, AZ, USA.
Ther Adv Ophthalmol. 2019 Aug 22;11:2515841419870366. doi: 10.1177/2515841419870366. eCollection 2019 Jan-Dec.
The objective of this article is to review the pharmacology, efficacy, and safety of lifitegrast and determine its role relative to other agents in the management of dry eye disease. A PubMed search (1946 to December 2018) using the terms and was conducted to identify relevant articles. or evaluations of lifitegrast published in the English language were eligible for inclusion. Phase II and III trials were selected for review of efficacy and safety. Four randomized controlled trials evaluated the efficacy and safety of lifitegrast 0.5% ophthalmic solution for 12 weeks, and 1 additional trial assessed safety for 1 year. In a majority of the trials, lifitegrast caused statistically significant improvements in inferior corneal fluorescein staining scores and eye dryness scores. The most common adverse effects were eye irritation, dysgeusia, and reduced visual acuity, and most were mild to moderate in severity. Lifitegrast has a novel mechanism of action and is safe and effective for the treatment of dry eye disease. At this time, lifitegrast may be considered as an option for patients who have an inadequate response to artificial tears.
本文的目的是综述lifitegrast的药理学、疗效和安全性，并确定其在干眼症治疗中相对于其他药物的作用。通过在PubMed数据库（1946年至2018年12月）中使用相关术语进行检索，以识别相关文章。纳入符合条件的以英文发表的关于lifitegrast的研究或评估。选择II期和III期试验来综述疗效和安全性。四项随机对照试验评估了0.5%lifitegrast滴眼液12周的疗效和安全性，另有一项试验评估了其1年的安全性。在大多数试验中，lifitegrast在统计学上显著改善了角膜下方荧光素染色评分和眼干评分。最常见的不良反应是眼部刺激、味觉障碍和视力下降，大多数为轻度至中度。Lifitegrast具有一种新机制，对干眼症治疗安全有效。目前，对于人工泪液治疗反应不佳的患者，可考虑将lifitegrast作为一种选择。
